Navigation Links
Moffitt Cancer Center Receives Prestigious SPORE Grant Worth More Than $10 Million
Date:9/2/2008

TAMPA, Fla., Sept. 2 /PRNewswire/ -- The National Cancer Institute (NCI) has awarded Dr. Gerold Bepler, program leader for thoracic oncology at Moffitt Cancer Center ( http://www.moffitt.org ), and his team a Specialized Programs of Research Excellence (SPORE) grant in lung cancer. The grant totals $10,475,090 over five years. This is Moffitt's first SPORE grant, which puts them in the company of other leading cancer centers like University of Texas M. D. Anderson Cancer Center, Johns Hopkins Hospital and Mayo Clinic.

"This grant acknowledges the continued translational work done by the entire lung team at Moffitt, which has been recognized nationally and internationally," Bepler said. "Our entire team is extremely honored to be recognized by a panel of national lung cancer experts at the level of the NCI. It will provide us the opportunity to continue and significantly enhance our efforts to contribute to the prevention and cure of lung cancer."

Lung cancer is the leading cause of cancer death for men and women. Florida is second behind California in the number of new lung cancer cases per year.
Moffitt will conduct four research projects with various team members.

1. E2Fs impact on therapeutic efficacy

-- Douglas Cress, Ph.D., Jiandong Chen, Ph.D., Bepler

2. -- Antitumor mechanism of src inhibitors

-- Eric Haura, M.D., Jin Cheng, M.D., Ph.D., and Jack Pledger, Ph.D.

3. Chemoprevention with enzasataurin

-- Bepler and Mark Alexandrow, Ph.D.

4. P53-based vaccine for small cell lung cancer

-- Dmitry Gabrilovich, M.D., Ph.D. and Scott Antonia, M.D., Ph.D.

For more information on the Lung Cancer SPOREs program, visit the NCI website: http://spores.nci.nih.gov/current/lung/lung.html

About H. Lee Moffitt Cancer Center & Research Institute

Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed in U.S. News & World Report as one of "America's Best Hospitals" for cancer. Moffitt's sole mission is to contribute to the prevention and cure of cancer.


'/>"/>
SOURCE H. Lee Moffitt Cancer Center & Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Moffitt Cancer Center Joins National Campaign To Implore Americans To Donate $1 To Accelerate Cancer Research
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
4. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. Novel Technology Breaks Through Cancer Pain
10. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
11. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... Savannah River Remediation LLC group evaluated ... NT-MAX Lake & Pond Sludge and Muck ... conjunction with Hexa Armor/ Rhombo cover manufactured by ... Discharge Elimination System requirements. The Savannah ... of elevated pH levels, above 8.5, especially during ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
(Date:11/29/2016)... -- BioDirection, a privately held medical device company developing ... of concussion and other traumatic brain injury (TBI), announced ... with the U.S. Food and Drug Administration (FDA) to ... the meeting company representatives reviewed plans for clinical development ... of a planned pilot trial. "We ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
Breaking Biology News(10 mins):